News

Medtronic's stock has been an underwhelming investment to hold on to in recent years. While it's up around 4% this year, over a five-year period its returns are negative -- down 15%.
Medtronic plc capped off its fiscal year with strong Q4 results, reporting $8.9 billion in revenue and double-digit earnings growth.
Q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organic Q4 GAAP diluted EPS of $0.82 increased 67%; non-GAAP diluted EPS of $1.62 increased 11% Q4 operating margin increased 380 ...
Over the last five years, Medtronic's stock has shown a favorable one-day return following its earnings announcements in 53% of instances. These favorable returns have had a median of 2.5% and a ...
What makes aDBS different is that it can adapt and fine-tune the stimulation in real time." (Cleveland Clinic) "Traditional DBS gives the same stimulation to the brain 24 hours a day.
Medtronic Bold thinking. Bolder actions. We are Medtronic. We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding ...
The United States Food and Drug Administration (FDA) recently approved the Medtronic Adaptive Deep Brain Stimulation (aDBS) system for use in the U.S. for patients with Parkinson's disease.
To apply the latest technology to Schena’s treatment, a representative for Medtronic, the company that makes the aDBS system, was present in a lunchroom crowded with doctors, research fellows ...
Medtronic faces a recruitment challenge: The medical robot and pacemaker company isn’t very well known outside of Minnesota, said Mark Smith, vice president for global talent acquisition ...
Drug delivery technology advances are improving and preserving the health of millions of people around the world. Our cover story explores next-generation inhalable vaccines and the nebulizer ...
But, he thought, “I’ve come this far”. The aDBS treatment banished Lipp’s cramping and helped him shed most medications. Last November, he completed the 2024 New York City Marathon.